Associations between Urinary and Dietary Selenium and Blood Metabolic Parameters in a Healthy Northern Italy Population

Teresa Urbano 1,†, Tommaso Filippini 1,†, Daniela Lasagni 2, Tiziana De Luca 2, Sabrina Sucato 3, Elisa Polledri 3, Francescouzziches 1, Marcella Malavolti 1, Claudia Baraldi 1, AnnaLisa Santachiara 5, Thelma A. Pertinhez 2,6, Roberto Baricchi 2, Silvia Fustinoni 3,7, and Marco Vinceti 1,8,*

Abstract: Selenium is both an essential nutrient and a highly toxic element, depending on its dose and chemical forms. We aimed to quantify urinary selenium excretion and dietary selenium intake in 137 healthy non-smoking blood donors living in the northern Italian province of Reggio Emilia. We assessed selenium status by determining urinary selenium levels (mean 26.77 μg/L) and by estimating dietary selenium intake (mean 84.09 μg/day) using a validated semi-quantitative food frequency questionnaire. Fasting blood levels of glucose, lipids, and thyroid-stimulating hormone were measured using automated laboratory procedures. Dietary and urinary selenium were correlated (beta coefficient (β) = 0.19). Despite this, the association of the two indicators with health endpoints tended to diverge. Using linear regression analysis adjusted for age, sex, body mass index, cotinine levels and alcohol intake, we observed a positive association between urinary selenium and blood triglyceride (β = 0.14), LDL-cholesterol (β = 0.07) and glucose levels (β = 0.08), and an inverse one with HDL-cholesterol (β = −0.12). Concerning dietary selenium, a slightly positive association could be found with glycemic levels only (β = 0.02), while a negative one emerged for other endpoints. The two selenium indicators showed conflicting and statistically highly imprecise associations with circulating TSH levels. Our findings suggest that higher selenium exposure is adversely associated with blood glucose levels and lipid profile. This is the case even at selenium exposures not exceeding tolerable upper intake levels according to current guidelines.

Keywords: dietary selenium; urinary selenium; biomarkers of exposure; glucose levels; lipid blood profile

1. Introduction

Over the last decades, a number of studies have tried to elucidate the controversial and intriguing role of the trace element selenium in human health. Selenium has a large spectrum of both nutritional and toxicological properties in humans [1], animals [2,3] and
plants [4], with a still uncertain balance between the two. In fact, the safe range of intake is not well defined and is still debated. Different choices have been made by different agencies based on very different rationales, while there is increasing awareness of the potential for low-dose selenium toxicity [5,6].

Several diseases and conditions have been linked to selenium deficiency and excess [6]. Over time, emphasis has been laid on suspected adverse effects on cancer risk and on the signs and symptoms of selenosis. A purported protective effect for cancer and cardiovascular disease was stressed at the turn of the century. However, the lack of evidence of a clear beneficial effect of selenium supplementation did not confirm such a preventive role [7]. In fact, more recent studies have linked selenium overexposure with excess risk of metabolic diseases such as type 2 diabetes [8], hyperlipidemia [9], non-alcoholic fatty liver disease [10] and neurodegenerative disease [5,11]. The possibility that selenium exerts adverse effects on human metabolism, in particular, is supported by converging evidence for type 2 diabetes from both experimental [12] and non-experimental [8] epidemiologic studies. However, the exact amount of selenium exposure that needs to be reached to increase metabolic adverse effects is still partly unclear [6,8]. In addition, evidence suggests the impact of selenium exposure on the thyroid gland, with indications of both adverse and beneficial effects depending on the amount and chemical form of selenium, study population and the thyroid-related endpoint investigated [13–15].

In humans, selenium exposure occurs in many different chemical forms [16–19]. Moreover, because selenium is ubiquitous to the environment, exposure is linked to different sources [5]. This causes it to influence related health effects and underlying biological properties, which are also modified by other dietary constituents [6,7]. However, the main route of exposure for most individuals is diet [20,21]. On the other hand, water, dietary supplements and exposure to environmental sources such as smoking [22] and motorized traffic exhaust [23] may be considered essentially trivial sources [6,20], with the exception of the rare occurrence of occupational exposure [24]. Different biomarkers have been proposed to assess selenium exposure, but the most commonly used and reliable ones are circulating selenium levels in serum, plasma and whole blood [25]. These biomarkers also allow for the assessment of the various selenium chemical species [6]. Other biomarkers that have been adopted to assess selenium contents are nails, toenails and hair [26]. These have several advantages. To begin with, they are informative about long-term selenium exposure. In addition, their sampling and collection are less invasive and, therefore, better tolerated by participants. Nonetheless, they are not suitable for speciation analysis and show a limited correlation with blood selenium levels and dietary selenium intake. For these reasons, they may not be adequate to monitor selenium overexposure [27], possibly owing to their inability to retain some circulating selenium species, such as inorganic ones [28]. Two more suitable indicators have been proposed to assess selenium exposure, i.e., dietary intake and urinary excretion levels. The first can be derived from validated semi-quantitative food frequency questionnaires and may allow us to evaluate selenium intake independently of metabolism and excretion [6]. The second is thought to be an appropriate indicator of recent exposure only [29].

In a group of healthy adults, we investigated the relation between selenium exposure, as assessed through dietary intake and urinary excretion levels, and metabolic endpoints, including blood levels of glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and thyroid-stimulating hormone.

2. Materials and Methods

2.1. Study Population

We recruited blood donors from the Transfusion Medicine Center ‘Casa del Dono’ of AUSL-IRCCS of Reggio Emilia, Northern Italy, from April 2017 to April 2019. Recruitment followed approval from the Reggio Emilia Ethics Committee (approval no. 2016/002799) and written informed consent from participants. To be enrolled in the study, all subjects had to be living in the province of Reggio Emilia, be aged 30–60 and be non-smokers.
A final number of 148 eligible subjects were accepted to participate in the study. Four participants later withdrew from the study, and an additional seven were excluded because of high urinary cotinine levels (>30 µg/L), inconsistent with the self-declared non-smoker status [30,31]. The final study population was eventually composed of 137 subjects.

After written informed consent was obtained, participants were asked to give a fasting blood and a urine sample. Participants also compiled a detailed questionnaire concerning lifestyle and habits. This included information on height and weight, marital status, education, occupational and residency history, smoking history (never or former smokers) and selenium-containing dietary supplement use. In addition, they were asked to fill in a validated semi-quantitative food frequency questionnaire (European Prospective Investigation into Cancer and Nutrition Food Frequency Questionnaire—EPIC FFQ) already used in previous studies [32,33]. Briefly, the EPIC FFQ allows one to assess dietary habits in the considered population. In particular, it investigates the frequency and amount (selected among three portion sizes) of 188 food items. The related intake of nutrients was calculated using a previously developed ad hoc software. We estimated daily dietary selenium intake by combining the trace-element average in food within the study area and food consumption patterns assessed through the FFQ.

2.2. Laboratory Analyses

2.2.1. Analytical Determination of Biochemical Parameters in Blood and Urine

Blood venous and urine samples were collected in a plastic tube and stored at −20 °C until use. Automatized laboratory procedures were used to quantify the following parameters: total cholesterol, HDL-cholesterol, triglycerides, glucose and thyroid-stimulating hormone, while LDL-cholesterol was calculated through the Friedewald formula [34]. Urinary cotinine, a biomarker of tobacco smoking, was measured by Liquid Chromatography with tandem mass spectrometry (LC/MS/MS) (TSQ Quantum Access, Thermo Scientific, Rodano, Italy) [31]. Subjects with mean urinary cotinine ≥ 100 µg/L were classified as active daily smokers. The use of the mean value of urinary cotinine to classify subjects is supported by the relatively long half-life of urinary cotinine (6–22 h) which makes this biomarker quite stable over the day in regular daily smokers.

2.2.2. Analytical Determination of Selenium in Urine

Before analysis, urine samples were thawed at room temperature for 2 h. Each sample was mixed and heated at 37 °C for 30 min to dissolve the sediment. An aliquot of 600 µL was transferred into a 10 mL polyethylene tube and added to 2.4 mL of an aqueous solution of nitric acid 0.05% v/v prepared by diluting ultrapure nitric acid (69% TraceSelect, Fluka, France), containing 7.5 µg/L of Scandium-45 (45Sc), Yttrium-89 (89Y) and Indium-111 (111In) as internal standards (Inorganic Ventures, Inc., Lakewood, NJ, USA). All solutions were prepared using Milli-Q® ultrapure water (conductivity 0.056 µS/cm) (Merck, Darmstadt, Germany). The urine samples were analyzed by inductively coupled plasma mass spectrometry (ICP-MS) X Series II (Thermo Electron Corporation, Rodano, Italy). The instrument was operated in collision cell mode (CCT-Ked), with 3.7 mL/min of helium used to reduce interference. For each sample, three replicates were run. The calibration curve was in the range of 0.2–70 µg/L. The calibration solutions were obtained by diluting a selenous acid standard solution containing selenium at 1 mg/mL (BDH, VWR International, Milano) with an aqueous solution of nitric acid 0.05% v/v in the presence of internal standards. The calibration curve was linear with a correlation coefficient ≥0.999. The limits of quantification (LOQs), calculated as ten times the standard deviation of the blank, amounted to 1.2 µg/L. Internal quality assurance was performed using two quality controls (QCs) for metals in urine: Lyphocheck Urine Metals Control, Level-1 (Bio-Rad Laboratories, Anaheim, CA, USA), and Seronorm® Level-1 (Sero AS, Billingstad, Norway). Before analysis, QCs were reconstituted in accordance with manufacturers’ instructions. QC accuracy was between 90% and 110% and precision ranged between 7% and 11%.
2.3. Data Analysis

We reported the percentile distribution of urinary selenium concentrations and dietary selenium intake, as well as fasting hematological parameters and urinary cotinine levels. Concerning the occurrence of extreme values, we found a subject with very high triglycerides, 574 mg/dL, and one with very high thyroid-stimulating hormone levels, 15.64 mU/mL, both of which we considered outliers and therefore winsorized at the 99th percentile. Only these two values were changed.

We assessed the association between urinary and dietary selenium concentrations, and between these selenium status indicators and the blood metabolic endpoints of glycemia and HDL-, LDL- and total cholesterol as well as triglycerides, by using crude and multivariable linear regression analyses. For the latter, age, sex, body mass index (BMI—as a continuous variable), cotinine levels and alcohol intake were included in the model as potential confounders. We used linear regression fitted on a restricted cubic spline model and based on three knots at fixed percentiles (10th, 50th and 90th). Moreover, we assessed the statistical precision of the estimates by computing their 95% confidence interval (CI). We used the ‘mkspline’, ‘regress’, ‘xbcrsplinei’ and ‘winsor’ routines of the Stata 17.1 software (Stata Corp., College Station, TX 2021, USA).

3. Results

This study included 137 participants, 62 men and 75 women, aged 30–60. Table 1 summarizes the main characteristics of the study population, i.e., sex, age, BMI, smoking habits, consumption of selenium-containing supplements, marital status, educational attainment levels and occupational group, according to the international standard classification of occupations (ISCO). The study population was mainly composed of men and women aged less than 50 years, who were normal weight and had never smoked in their lifetime.

Table 2 shows the distribution of the blood parameters in the study participants and the urinary and dietary selenium concentrations. Median urinary selenium excretion was 22.02 µg/L (interquartile range (IQR) 14.64–37.15 µg/L), while the median daily dietary intake was 78.74 µg (IQR 62.62–101.48 µg/day), with higher values in men compared with women. Men also exhibited higher blood glucose and higher triglyceride levels, along with higher levels of thyroid-stimulating hormone. Conversely, they had lower levels of LDL-, HDL- and total cholesterol.

Using urinary selenium as a dependent variable and dietary selenium intake as an independent one, the linear regression estimate (β coefficient) was 0.19 (95% CI 0.10, 0.27) and 0.18 (95% CI 0.10, 0.27) in the crude and multivariable adjusted models, respectively. Both in the crude and multivariable spline regression analysis, which was adjusted for sex, age, BMI, cotinine levels and alcohol intake, we found a positive and almost linear correlation between urinary and dietary selenium. However, the strength of the association tended to increase at around 100 µg of daily selenium intake and above (Figure 1 and Figure S1).
### Table 1. Characteristics of the study population and mean urinary and dietary selenium (Se) concentrations for each subgroup.

| Characteristics | All |          |        |          |        |        |        |          |        |        |          |        |        |        |
|-----------------|-----|----------|--------|----------|--------|--------|--------|----------|--------|--------|----------|--------|--------|--------|
|                 | N   | %        | Urinary Se (µg/L) | Men | N   | %        | Urinary Se (µg/L) | Women | N   | %        | Urinary Se (µg/L) | Men | N   | %        | Urinary Se (µg/L) | Women |
| Overall         | 137 | 100      | 26.77 | 84.09    | 62    | 45.3    | 29.0    | 89.97 | 75    | 54.7    | 24.92    | 79.23  | |
| Age             |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| <50 years       | 80  | 58.4     | 27.23 | 86.13    | 39    | 62.9    | 30.17  | 90.94 | 41    | 54.7    | 24.44    | 81.55  | |
| ≥50 years       | 57  | 41.6     | 26.12 | 81.24    | 23    | 37.1    | 27.04  | 88.32 | 34    | 45.3    | 25.50    | 76.44  | |
| BMI             |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| <25 kg/m²       | 74  | 54.0     | 25.59 | 82.21    | 32    | 51.6    | 28.47  | 91.10 | 42    | 56.0    | 23.39    | 75.44  | |
| ≥25 kg/m²–<30 kg/m² | 50  | 36.5     | 28.58 | 84.22    | 27    | 43.6    | 29.49  | 87.04 | 23    | 30.7    | 27.52    | 80.92  | |
| ≥30 kg/m²       | 13  | 9.5      | 26.52 | 94.31    | 3     | 4.8     | 30.40  | 104.27| 10    | 13.3    | 25.36    | 91.32  | |
| Smoking habits  |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| Never           | 101 | 73.7     | 26.10 | 83.95    | 45    | 72.6    | 28.77  | 88.60 | 56    | 74.7    | 23.95    | 80.21  | |
| Former          | 36  | 26.3     | 28.66 | 84.50    | 17    | 27.4    | 29.64  | 93.60 | 19    | 25.3    | 27.79    | 76.36  | |
| Selenium supplement users |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| No              | 94  | 68.6     | 25.06 | 87.56    | 46    | 74.2    | 29.80  | 94.65 | 48    | 64.0    | 22.46    | 80.76  | |
| Yes             | 23  | 16.8     | 29.08 | 80.14    | 6     | 9.7     | 27.75  | 72.37 | 17    | 22.7    | 29.55    | 82.88  | |
| Former          | 20  | 14.6     | 27.48 | 72.34    | 10    | 16.1    | 26.11  | 78.97 | 10    | 13.3    | 28.85    | 65.71  | |
| Marital status  |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| Married/unmarried partner | 97  | 70.8     | 26.78 | 83.10    | 44    | 71.0    | 29.72  | 87.69 | 53    | 70.7    | 24.34    | 79.28  | |
| Single          | 26  | 19.0     | 27.65 | 87.72    | 12    | 19.4    | 28.80  | 104.28| 14    | 18.7    | 26.66    | 73.52  | |
| Separated/divorced | 14  | 10.2     | 25.07 | 84.26    | 6     | 9.6     | 24.20  | 78.05 | 8     | 10.7    | 25.73    | 88.91  | |
| Educational level |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| Elementary school | 2   | 1.5      | 37.26 | 146.96   | 2     | 3.2     | 37.26  | 146.96| -     | -       | -        | -      | -      | -      |
| Middle school   | 20  | 14.6     | 25.99 | 84.79    | 8     | 12.9    | 29.46  | 80.08 | 12    | 16.0    | 23.67    | 87.92  | |
| High school     | 66  | 48.2     | 23.87 | 82.73    | 28    | 45.2    | 24.98  | 90.92 | 38    | 50.7    | 23.05    | 76.70  | |
| College or more | 49  | 35.8     | 30.57 | 83.07    | 24    | 38.7    | 32.87  | 87.40 | 25    | 33.3    | 26.37    | 78.92  | |
| Occupation (ISCO) |     |          |        |          |       |        |        |       |       |        |          |        |       |        |
| Managers        | 9   | 6.6      | 21.30 | 84.83    | 6     | 9.7     | 21.42  | 80.45 | 3     | 4.0     | 21.04    | 93.60  | |
| Professionals   | 26  | 19.0     | 30.16 | 91.07    | 12    | 19.4    | 33.81  | 104.05| 14    | 18.7    | 27.03    | 79.93  | |
| Technicians/associate professionals | 21  | 15.3     | 25.96 | 82.74    | 11    | 17.7    | 23.41  | 89.03 | 10    | 13.3    | 28.75    | 75.82  | |
| Clerical support workers | 43  | 31.4     | 25.78 | 79.34    | 12    | 19.4    | 32.10  | 82.18 | 31    | 41.3    | 22.99    | 78.24  | |
| Service and sales workers | 11  | 8.0      | 26.65 | 71.98    | 2     | 3.2     | 22.71  | 81.07 | 9     | 12.0    | 27.52    | 69.96  | |
| Craft and related trade workers | 10  | 7.3      | 22.16 | 80.73    | 8     | 12.9    | 24.80  | 82.40 | 2     | 2.7     | 11.61    | 74.09  | |
| Plant and machine operators | 11  | 8.0      | 35.63 | 94.40    | 8     | 12.9    | 36.22  | 100.51| 3     | 4.0     | 34.05    | 78.12  | |
| Elementary occupations | 6   | 4.4      | 21.92 | 100.44   | 3     | 4.8     | 25.78  | 85.25 | 3     | 4.0     | 18.07    | 115.63 | |

Abbreviations: ISCO, International Standard Classification of Occupations.
Table 2. Median, 25th and 75th percentile of urinary and dietary selenium distribution and fasting blood parameters in the study population (n = 137).

| Parameter                      | 25th   | Median | 75th   |
|--------------------------------|--------|--------|--------|
| **All participants**           |        |        |        |
| Selenium                       |        |        |        |
| Dietary intake (µg/day)        | 62.62  | 78.74  | 101.48 |
| Urinary concentration (µg/L)  | 14.64  | 22.02  | 37.15  |
| **Blood parameter**           |        |        |        |
| Glycemia (mg/dL)              | 81     | 86     | 91     |
| Total cholesterol (mg/dL)     | 184    | 204    | 224    |
| HDL-cholesterol (mg/dL)       | 51     | 59     | 69     |
| LDL-cholesterol (mg/dL)       | 109    | 124    | 144    |
| Triglycerides (mg/dL)         | 62     | 78     | 112    |
| Thyroid-stimulating hormone (mU/mL) | 1.18 | 1.59  | 2.21   |
| Urinary cotinine levels (µg/L) | 0.05   | 0.27   | 0.86   |
| **Men**                       |        |        |        |
| Selenium                       |        |        |        |
| Dietary intake (µg/day)        | 69.77  | 88.37  | 108.28 |
| Urinary concentration (µg/L)  | 16.72  | 24.21  | 39.20  |
| **Blood parameter**           |        |        |        |
| Glycemia (mg/dL)              | 82     | 88     | 94     |
| Total cholesterol (mg/dL)     | 177    | 192    | 219    |
| HDL-cholesterol (mg/dL)       | 46     | 52     | 58     |
| LDL-cholesterol (mg/dL)       | 101    | 120    | 142    |
| Triglycerides (mg/dL)         | 67     | 85     | 135    |
| Thyroid-stimulating hormone (mU/mL) | 1.16 | 1.75  | 2.34   |
| Urinary cotinine levels (µg/L) | 0.05   | 0.20   | 0.77   |
| **Women**                     |        |        |        |
| Selenium                       |        |        |        |
| Dietary intake (µg/day)        | 54.77  | 71.06  | 91.68  |
| Urinary concentration (µg/L)  | 13.30  | 21.30  | 34.66  |
| **Blood parameter**           |        |        |        |
| Glycemia (mg/dL)              | 79     | 85     | 89     |
| Total cholesterol (mg/dL)     | 192    | 210    | 227    |
| HDL-cholesterol (mg/dL)       | 57     | 67     | 73     |
| LDL-cholesterol (mg/dL)       | 112    | 125    | 146    |
| Triglycerides (mg/dL)         | 58     | 73     | 106    |
| Thyroid-stimulating hormone (mU/mL) | 1.18 | 1.54  | 2.16   |
| Urinary cotinine levels (µg/L) | 0.05   | 0.32   | 0.94   |

Figure 1. Spline regression analysis of urinary and dietary selenium (Se) levels. Solid line represents multivariable analysis (adjusted for age, sex, body mass index, cotinine levels and alcohol intake) and shaded area indicates upper and lower confidence interval limits.
In the linear regression analysis, urinary selenium excretion was positively associated with blood glucose, LDL-cholesterol, triglyceride and (slightly and very imprecisely) thyroid-stimulating hormone levels, in both the crude and the multivariable models. The relation was negative with HDL-cholesterol (Table 3). These results were generally confirmed in multivariable spline regression analyses (Figure 2), with limited evidence of any threshold or non-linear shape of the association.

Table 3. Linear regression analysis of glycemia, lipid profile variables and thyroid-stimulating hormone versus urinary selenium (Se) concentration and dietary Se intake biomarkers as independent variables. Crude model and adjusted for age, sex, body mass index (BMI), cotinine levels and alcohol intake along with their 95% confidence interval (CI).

| Linear Regression Analysis | Crude | Adjusted |
|---------------------------|-------|----------|
| Urinary Se concentration (µg/L) | β | (95% CI) | β | (95% CI) |
| Glycemia (mg/dL) | 0.08 | (−0.01, 0.18) | 0.08 | (−0.02, 0.16) |
| Total cholesterol (mg/dL) | −0.10 | (−0.43, 0.22) | −0.01 | (−0.32, 0.32) |
| HDL-cholesterol (mg/dL) | −0.18 | (−0.33, −0.04) | −0.12 | (−0.25, 0.003) |
| LDL-cholesterol (mg/dL) | 0.03 | (−0.25, 0.32) | 0.07 | (−0.21, 0.36) |
| Triglycerides (mg/dL) * | 0.16 | (−0.35, 0.67) | 0.14 | (−0.35, 0.62) |
| Thyroid-stimulating hormone (mU/mL) * | 0.005 | (−0.005, 0.015) | 0.005 | (−0.005, 0.015) |
| Dietary Se intake (µg/day) | β | (95% CI) | β | (95% CI) |
| Glycemia (mg/dL) | 0.04 | (−0.01, 0.09) | 0.02 | (−0.02, 0.07) |
| Total cholesterol (mg/dL) | −0.22 | (−0.39, −0.05) | −0.20 | (−0.37, −0.03) |
| HDL-cholesterol (mg/dL) | −0.07 | (−0.15, 0.01) | −0.02 | (−0.09, 0.05) |
| LDL-cholesterol (mg/dL) | −0.11 | (−0.26, 0.04) | −0.11 | (−0.27, 0.04) |
| Triglycerides (mg/dL) * | −0.16 | (−0.43, 0.11) | −0.27 | (−0.53, −0.02) |
| Thyroid-stimulating hormone (mU/mL) * | −0.001 | (−0.007, 0.004) | −0.001 | (−0.007, 0.004) |

*Linear regression estimates calculated using winsorized values.

As regards the correlation between dietary selenium intake and the endpoints, we found a positive association with glycemia in the linear regression analysis. In the spline regression analysis, furthermore, the shape of the association resembled an inverted U, changing its direction around 90 µg/day (Figure 3). Dietary selenium intake was also slightly inversely correlated with HDL-, LDL- and total cholesterol and with triglycerides in both crude and multivariable analyses (Table 3). In the spline regression analysis, there was an indication of a U-shaped association with blood glucose and of a U-shaped curve with HDL-cholesterol. At the same time, the remaining associations were smoothly negative with the exception of a substantially null association with thyroid-stimulating hormone, with highly scattered intersection points (Figure 3). Concerning thyroid-stimulating hormone, this showed a slightly positive association with urinary selenium in the linear regression analysis, while a negative one was observed with dietary intake. However, all regression estimates for TSH were statistically most unstable, as shown by the wide confidence intervals. In addition, spline regression analysis added limited evidence of a relation of selenium (urinary and particularly dietary) with the blood concentrations of this hormone.

Sex-stratified analyses showed some differences for the male and female population, as reported in Tables S1 and S2. In the linear regression analysis, in men we found a strong positive association between urinary selenium concentration and triglycerides and a weaker but still positive association with glucose, and LDL- and total cholesterol levels. A negative one was observed with HDL-cholesterol. Subgroup analyses in women showed the same positive and negative associations with glucose and HDL-cholesterol levels, respectively, while the association was null with LDL-cholesterol levels, and negative with total cholesterol and triglyceride levels. A negative and very imprecise association was observed with thyroid-stimulating hormone levels. As regards dietary selenium intake, we found slightly positive associations with glucose levels in both men and women, although stronger in the latter, while negative associations emerged with triglycerides as well as HDL-, LDL- and total cholesterol. The association between urinary selenium and thyroid-
stimulating hormone levels was found to be slightly negative in men and weakly positive in women, although both estimates were statistically very unstable.

Additionally, the sex-specific spline regression analyses showed differences from the slopes computed for the overall population. Concerning urinary selenium concentration, both men and women experienced the same slightly positive association with blood glucose levels and LDL-cholesterol. Total cholesterol was slightly positively associated with urinary selenium in men, while a negative association was observed in women above 30 µg/L. The association with HDL-cholesterol was different in the two sexes, since we found a U-shaped curve in men, with clear evidence of a decrease up to 30 µg/L and higher values above this apparent threshold. The pattern was almost the opposite in women, with a decreasing trend above a 30 µg/L concentration of urinary selenium. The association with triglycerides was generally positive in men, although a plateau was reached at around 40 µg/L, while in women the relation was negative up to 20 µg/L and then became positive above that value. As in the linear regression analyses, the association between urinary selenium and thyroid-stimulating hormone was different for the two sexes. In fact, an entirely positive and almost linear pattern was observed in men. In women, on the other hand, the positive association flattened around 30 µg/L and the curve then started to decrease, thus showing an inverted U-shaped pattern (Figures S2 and S3).

Furthermore, regarding the associations between dietary selenium intake and health-related endpoints, we found several sex-related differences. Glucose levels were uniformly and positively associated in men, while an inverted U-shaped curve was observed in women above 100 µg/day. The relation with total cholesterol was negative in both subgroups, although its shape was less linear in men. The curve for HDL-cholesterol was similarly U-shaped in men and women, although more flattened in the former subgroup. The association with LDL-cholesterol was U-shaped and inverted U-shaped in men and women, respectively, in both cases changing its direction above 100 µg/day. Triglycerides were negatively related to dietary selenium in both subgroups, although the curves decreased at different intake levels. Concerning the relation with thyroid-stimulating hormone, an almost null association was reported for women, while a negative association was observed in men up to 100 µg/day; above that value, the curve inverted its direction and slightly increased, showing a U-shaped pattern (Figures S4 and S5).
Figure 2. Spline regression analysis of urinary selenium (Se) levels, glycemic and lipid profile variables and thyroid-stimulating hormone (TSH). Solid lines represent multivariable analysis (adjusted for age, sex, body mass index, cotinine levels and alcohol intake) and the shaded area indicates upper and lower confidence interval limits.
Figure 3. Spline regression analysis of dietary selenium (Se) levels, glycemic and lipid profile variables and thyroid-stimulating hormone (TSH). Solid lines represent multivariable analysis (adjusted for age, sex, body mass index, cotinine levels and alcohol intake) and the shaded area indicates upper and lower confidence interval limits.
4. Discussion

While there is much uncertainty about the role of selenium in human health, convincing evidence has been provided to support its ability to increase the risk of metabolic disease even at unexpectedly low exposure levels. This is clearly the case for type 2 diabetes based on randomized controlled trials [12] and observational studies [8], but it could also be true for hypertension and non-alcoholic fatty liver disease [10,35,36]. An association, either adverse or beneficial, between selenium status and lipid profile is considerably more controversial, due to conflicting findings from both experimental and non-experimental human studies [37–42]. In addition, there is still considerable uncertainty about what threshold of selenium exposure can trigger such adverse metabolic effects. Overall, these issues bear on the identification of a safe range of selenium intake, which has generated considerable interest and led to different approaches and standards across countries and the scientific community [6,43–46].

In this study, evidence appears to substantially validate the assessment of selenium intake through questionnaires on urinary excretion of the element, although such relation has not always been found [24,25,47,48]. It should also be noted that this relation was evident despite the non-irrelevant number of study participants reporting occasional use of selenium-containing dietary supplements. This tends to reduce the reliability of assessments of selenium intake based only on a food frequency questionnaire, as in this case.

Given the positive association between urinary and dietary selenium we detected, it appears surprising that most relations between exposure and health endpoints observed through multivariable regression analysis highlighted an inconsistency between these two indicators of selenium exposure in terms of the direction, strength and statistical precision of the associations. At the same time, it must be noted that the correlation between these two indicators of selenium exposure was positive, but not very strong. The reasons for such partial lack of association could be twofold: first, the different exposure timeframe implied by the two methods, which is longer for dietary selenium intake (approximately one year); secondly, the uncertainty inherent in the dietary assessment methodologies, i.e., an inaccurate evaluation of both participants’ food intake and the selenium content of food items. In addition, such a discrepancy, as well as a lower capacity to correlate with the health endpoints of estimated dietary selenium intake compared with the biomarker, could be due to differences across study participants at two levels: first of all, in terms of diet composition, due to other dietary constituents influencing selenium absorption; secondly, in gastrointestinal absorption capacity. In this study population, therefore, we assume that the biomarker, i.e., urinary selenium concentrations, provides a better estimate of the bioavailable selenium pool in the study participants.

Evidence suggests a detrimental effect of selenium exposure on glucose and lipid metabolism. This is supported by two elements. The first is the positive association between urinary selenium concentrations and both blood glucose and two lipid parameters, such as LDL-cholesterol and triglycerides. The second is the negative association with HDL-cholesterol in both crude and adjusted analyses. This was the case despite the overall amount of selenium exposure falling in the expected range for both the Italian and more generally the European populations [21,26,49], and despite the fact that these associations were weak and generally statistically imprecise. The possibility that selenium may increase glycemia has been suggested by some prospective [50,51] and cross-sectional or case-control studies [50,52–54], although not all cohort studies are consistent [6,55]. In addition, a positive association between selenium exposure and glycemia is strongly supported by experimental and non-experimental studies on selenium and type 2 diabetes, with randomized controlled trials consistently showing a relation between selenium supplementation and disease risk [12]. The association was further supported by observational studies providing evidence of increasing diabetes risk above a threshold of selenium exposure at around 80 µg of daily intake [8].
The association of adverse lipid profile endpoints with urinary selenium is not entirely surprising, given the dose–response association between higher blood selenium concentrations and metabolic syndrome, higher triglycerides and LDL-cholesterol, as well as the lower HDL-cholesterol consistently found in the National Health and Nutrition Examination Surveys (NHANES) and other studies [39,52,54,56–58]. Conversely, randomized controlled trials have shown little if any effect of selenium supplementation on the lipid profile [38,40]. In those studies, however, high-selenium yeast was used to increase selenium intake, and the specific selenium species released by that source may be different from those characterizing the usual diet. It must also be noted that the other indicator of selenium exposure in our study, namely the assessment of the dietary intake of the element, showed neither a clear nor a consistent association with the lipid profiles. The only exception to this was the inverse association with HDL-cholesterol, which was also the lipid variable most strongly associated with urinary selenium concentrations. Overall, the inverse and almost linear association between urinary selenium exposure and HDL-cholesterol, as well as the positive association with triglyceride levels, can be considered the most relevant and consistent finding of our study with reference to the lipid profile. Moreover, it suggests the deleterious effect of selenium even at the rather low amounts of exposure characterizing the study population, which has so far been considered to be safe according to current recommended dietary values [49,59].

To the metabolic endpoints we also added an endocrine parameter, thyroid-stimulating hormone, whose association with selenium was conflicted across the two exposure indicators used in the study and is substantially unclear. The interaction between selenium intake and thyroid hormone status appears to be complex and largely depends on the amount of exposure, the chemical forms of selenium involved, the specific thyroid hormones under investigation and possible abnormalities in thyroid gland function and disease [6,46]. Selenium administered as selenized yeast (therefore presumably as selenomethionine) decreased thyroid-stimulating hormone levels compared with placebo in a randomized controlled trial [60] and in a subgroup of pregnant women with mild to moderate iodine deficiency [61]. On the other hand, little evidence of any effect emerged from another trial in the UK [19] and a small trial in the US [62]. It must be noted that an inhibitory effect of selenium administration on triiodothyronine and thyroxine and a rise in thyroid-stimulating hormone have been noted in some human studies. However, the exact amount of selenium exposure at which this may occur is unclear [15]. Unfortunately, we did not assess the full spectrum of thyroid hormones in this study. Therefore, we could not test the possibility that the slightly positive and statistically imprecise association between urinary selenium and thyroid-stimulating hormone may be due to a slight inhibitory effect of selenium on triiodothyronine and thyroxine synthesis.

In our study, we also assessed the sex-related differences between selenium and the metabolic endpoints, finding some evidence of a stronger and more adverse association between selenium and metabolic endpoints in men compared with women. In recent years, new evidence has emerged in relation to sexual dimorphism in glucose and lipid metabolism [63,64]. As their molecular mechanisms start to be revealed, some animal and laboratory studies suggest that the tissue distribution of selenium may be affected by hormone levels, and that interactions exist between sex hormones, particularly estrogens, and selenium metabolism and activity parameters [65–69]. This supports the possibility that the effects of selenium differ according to sex, which should be noted with reference to its capacity to alter metabolic disease risk [70,71]. Both in the present study and in previous reports, however, the effect estimates were too statistically unstable to allow for a meaningful assessment of sex as an effect modifier of the adverse metabolic effects of selenium and selenium species.

Among the limitations of this study is its non-experimental design. This precludes the possibility of selectively attributing the trends and changes in health endpoints to variation in selenium exposure, given the potential for confounding due to unmeasured dietary and lifestyle factors. On the other hand, the presence of clinical and subclinical disease biasing
both selenium intake and metabolism is very unlikely to have occurred in a substantial way in our study population. In fact, our carefully selected 'healthy' volunteers were also closely monitored with reference to their blood donation. Another limitation is that in this report we did not consider the chemical species of selenium found in foods and in the body (blood and urine). This should be assessed in the context of the limited information about selenium speciation in food, and bearing in mind that the determination of the chemical form of the element in urine is very rarely performed. The specificity of both nutritional and toxic properties of selenium critically depends on their chemical species [16,17,72,73], and this may also be true for the adverse effects on metabolic parameters. Finally, the potential mechanisms underpinning the adverse metabolic effects of selenium should be investigated in a more in-depth fashion, focusing on the possible influence of selenium species on redox status [74–76], protein integrity [77] and the microbiome—a less investigated but potentially interesting lead due to its connection with metabolic and chronic diseases [78,79].

5. Conclusions

In conclusion, our findings provide evidence for a positive and almost linear associations between urinary selenium and glycemic and triglyceride levels, and a negative relation with LDL-cholesterol concentrations. On the other hand, dietary selenium intake was more weakly and non-linearly associated with most of the endpoints considered. If confirmed by further studies, our results may add to the available evidence at two levels: first of all in reconsidering the safer levels of selenium intake, and secondly in establishing which indicators of selenium exposure are more suitable for the assessment of its toxic effects.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/antiox10081193/s1.

Author Contributions: Conceptualization, T.F. and M.V.; methodology, T.F., M.V. and S.F.; formal analysis, T.U., T.F., S.S. and E.P.; resources and recruitment, D.L. and T.D.L.; data curation, T.U., T.F., M.M., F.B., C.B. and T.A.P.; writing—original draft preparation, T.U.; writing—review and editing, all authors; supervision, A.S. and R.B.; project administration, M.V.; funding acquisition, R.B. and M.V. All authors have read and agreed to the published version of the manuscript.

Funding: Filippini, Malavolti, Urbano and Vinceti were supported by the grant “Dipartimenti di Eccellenza 2018–2022” to the UNIMORE Department of Biomedical, Metabolic and Neural Sciences from the Italian Ministry of Education, University and Research. Filippini was supported by the grant ‘UNIMORE FAR IMPULSO 2020’ (no. 494/2020) from the University of Modena and Reggio Emilia. Vinceti was supported by the Reggio Emilia Health Authority of the National Health Service.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Reggio Emilia Ethics Committee (approval no. 2016/002799).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study may be available on reasonable request from the corresponding author. The data are not publicly available due to privacy and legal restrictions.

Acknowledgments: We acknowledge the collaboration of the personnel of Transfusion Medicine Unit of AUSL-IRCCS of Reggio Emilia, staff and volunteers of AVIS-Section of Reggio Emilia and all blood donors who participated in this study.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Jablonska, E.; Vinceti, M. Selenium and human health: Witnessing a Copernican revolution? J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Res. 2015, 33, 328–368. [CrossRef]

2. Kasaikina, M.V.; Turanov, A.A.; Avanesov, A.; Schweizer, U.; Seeher, S.; Bronson, R.T.; Novoselov, S.N.; Carlson, B.A.; Hatfield, D.L.; Gladyshev, V.N. Contrasting roles of dietary selenium and selenoproteins in chemically induced hepatocarcinogenesis. Carcinogenesis 2013, 34, 1089–1095. [CrossRef]

3. Varlamova, E.G.; Cheremushkina, I.V. Contribution of mammalian selenocysteine-containing proteins to carcinogenesis. J. Trace Elem. Med. Biol. 2017, 39, 76–85. [CrossRef]

4. Kolbert, Z.; Molnar, A.; Feigl, G.; Van Hoewyk, D. Plant selenium toxicity: Proteome in the crosshairs. J. Plant Physiol. 2019, 232, 291–300. [CrossRef]

5. Vinceti, M.; Filippini, T.; Cilloni, S.; Crespi, C.M. The epidemiology of selenium and human cancer. Adv. Cancer Res. 2017, 136, 1–48. [CrossRef]

6. Vinceti, M.; Filippini, T.; Wise, L.A. Environmental selenium and human health: An update. Curr. Environ. Health Rep. 2018, 5, 464–485. [CrossRef]

7. Vinceti, M.; Filippini, T.; Del Giovane, C.; Dennert, G.; Zwahlen, M.; Brinkman, M.; Zeegers, M.P.A.; Horneber, M.; D’Amico, R.; Crespi, C.M. Selenium for preventing cancer. Cochrane Database Syst. Rev. 2018, 2018, CD005195. [CrossRef] [PubMed]

8. Vinceti, M.; Filippini, T.; Wise, L.A.; Rothman, K.J. A systematic review and dose-response meta-analysis of exposure to environmental selenium and the risk of type 2 diabetes in nonexperimental studies. Environ. Res. 2021, 197, 111210. [CrossRef] [PubMed]

9. Ju, W.; Ji, M.; Li, X.; Li, Z.; Wu, G.; Fu, X.; Yang, X.; Gao, X. Relationship between higher serum selenium level and adverse blood lipid profile. Clin. Nutr. 2018, 37, 1512–1517. [CrossRef] [PubMed]

10. Wang, X.; Seo, Y.A.; Park, S.K. Serum selenium and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011–2016. Environ. Res. 2021, 197, 111190. [CrossRef] [PubMed]

11. Vinceti, M.; Chiari, A.; Eichmuller, M.; Rothman, K.J.; Filippini, T.; Malagoli, C.; Weuve, J.; Tondelli, M.; Zamboni, G.; Nichelli, P.F.; et al. A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment. Alzheimers Res. Ther. 2017, 9, 100. [CrossRef]

12. Vinceti, M.; Filippini, T.; Rothman, K.J. Selenium exposure and the risk of type 2 diabetes: A systematic review and meta-analysis. Eur. J. Epidemiol. 2018, 33, 789–810. [CrossRef] [PubMed]

13. Hegeduš, L.; Bonnema, S.J.; Winther, K.H. Selenium in the treatment of thyroid diseases: An element in search of the relevant indications? Eur. Thyroid J. 2016, 5, 149–151. [CrossRef]

14. Negro, R.; Attanasio, R.; Grimaldi, F.; Marcocci, C.; Guglielmi, R.; Papini, E. A 2016 Italian survey about the clinical use of selenium in thyroid disease. Eur. Thyroid J. 2016, 5, 164–170. [CrossRef]

15. Vinceti, M.; Wei, E.T.; Malagoli, C.; Bergomi, M.; Vivoli, G. Adverse health effects of selenium in humans. Rev. Environ. Health 2001, 16, 233–251. [CrossRef]

16. Fairweather-Tait, S.J.; Collings, R.; Hurst, R. Selenium bioavailability: Current knowledge and future research requirements. Am. J. Clin. Nutr. 2010, 91, 1484S–1491S. [CrossRef]

17. Fan, A.M.; Vinceti, M. Selenium and its Compounds. In Hamilton & Hardy’s Industrial Toxicology; Wiley-Blackwell: Hoboken, NJ, USA, 2015; pp. 205–228.

18. Michalke, B.; Berthele, A. Contribution to selenium speciation in cerebrospinal fluid samples. J. Anal. At. Spectrom. 2011, 26, 165–170. [CrossRef]

19. Rayman, M.P.; Thompson, A.J.; Bekaert, B.; Catterick, J.; Galassini, R.; Hall, E.; Warren-Perry, M.; Beckett, G.J. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am. J. Clin. Nutr. 2008, 87, 370–378. [CrossRef] [PubMed]

20. Filippini, T.; Michalke, B.; Wise, L.A.; Malagoli, C.; Malavolti, M.; Vescovi, L.; Salvia, C.; Bargellini, A.; Sieri, S.; Krogh, V.; et al. Diet composition and serum levels of selenium species: A cross-sectional study. Food Chem. Toxicol. 2018, 115, 482–490. [CrossRef] [PubMed]

21. Filippini, T.; Cilloni, S.; Malavolti, M.; Violi, F.; Malagoli, C.; Tesauro, M.; Bottecchi, I.; Ferrari, A.; Vescovi, L.; Vinceti, M. Dietary intake of cadmium, chromium, copper, manganese, selenium and zinc in a Northern Italy community. J. Trace Elem. Med. Biol. 2018, 50, 508–517. [CrossRef]

22. Bogden, J.D.; Kemp, F.W.; Buse, M.; Third, I.S.; Louria, D.B.; Forgacs, J.; Llanos, G.; Moncya Terrones, I. Composition of tobaccos from countries with high and low incidences of lung cancer. I. Selenium, polonium-210, Alternaria, tar, and nicotine. J. Natl. Cancer Inst. 1981, 66, 27–31. [CrossRef]

23. Heck, J.E.; Park, A.S.; Qiu, J.; Cockburn, M.; Ritz, B. Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood. Int. J. Hyg. Environ. Health 2014, 217, 662–668. [CrossRef]

24. Goen, T.; Schaller, B.; Jager, T.; Brau-Dumler, C.; Schaller, K.H.; Drexler, H. Biological monitoring of exposure and effects in workers employed in a selenium-processing plant. Int. Arch. Occup. Environ. Health 2015, 88, 623–630. [CrossRef]

25. Ashton, K.; Hooper, L.; Harvey, L.J.; Hurst, R.; Casgrain, A.; Fairweather-Tait, S.J. Methods of assessment of selenium status in humans: A systematic review. Am. J. Clin. Nutr. 2009, 89, 2028S–2039S. [CrossRef] [PubMed]
26. Fairweather-Tait, S.J.; Bao, Y.; Broadley, M.R.; Collings, R.; Ford, D.; Hesketh, J.E.; Hurst, R. Selenium in human health and disease. Antioxid. Redox Signal. 2011, 14, 1337–1383. [CrossRef]

27. Chawla, R.; Filippini, T.; Loomba, R.; Cilloni, S.; Dhillon, K.S.; Vinceti, M. Exposure to a high selenium environment in Punjab, India: Biomarkers and health conditions. Sci. Total. Environ. 2020, 719, 134541. [CrossRef] [PubMed]

28. Filippini, T; Ferrari, A; Michalke, B; Grill, P; Vescovi, L; Salvia, C; Malagoli, C; Malavolti, M; Sieri, S; Krogh, V; et al. Toenail selenium as an indicator of environmental exposure: A cross-sectional study. Mol. Med. Rep. 2017, 15, 3405–3412. [CrossRef]

29. Hawkes, W.C.; Richter, B.D.; Alkan, Z.; Souza, E.C.; Derricote, M.; Mackey, B.E.; Bonnel, E.L. Response of selenium status indicators to supplementation of healthy North American men with high-selenium yeast. Biol. Trace Elem. Res. 2008, 122, 107–121. [CrossRef] [PubMed]

30. Campo, L.; Polledri, E.; Bechtold, P.; Gatti, G.; Ranzi, A.; Lauriola, P.; Goldoni, C.A.; Bertazzi, P.A.; Fusinoni, S. Determinants of active and environmental exposure to tobacco smoke and upper reference value of urinary cotinine in not exposed individuals. Environ. Res. 2016, 148, 154–163. [CrossRef] [PubMed]

31. Fusinoni, S.; Campo, L.; Polledri, E.; Mercadante, R.; Erspermer, L.; Ranzi, A.; Lauriola, P.; Goldoni, C.A.; Bertazzi, P. A validated method for urinary cotinine quantification used to classify active and environmental tobacco smoke exposure. Curr. Anal. Chem. 2013, 9, 447–456. [CrossRef]

32. Malavolti, M.; Cilloni, S.; Wise, L.A.; Violi, F; Malagoli, C.; Vescovi, L.; Vinceti, M. Intake of arsenic and mercury from fish and seafood in a Northern Italy community. Food Chem. Toxicol. 2018, 116, 20–26. [CrossRef]

33. Malavolti, M.; Fairweather-Tait, S.J.; Malagoli, C.; Vescovi, L.; Vinceti, M.; Filippini, T. Lead exposure in an Italian population: Food content, dietary intake and risk assessment. Food Res. Int. 2020, 137, 109370. [CrossRef]

34. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499–502. [CrossRef]

35. Su, L.; Jin, Y.; Unverzagt, F.W.; Liang, C.; Cheng, Y.; Hake, A.M.; Kuruppu, D.; Ma, F.; Liu, J.; Chen, C.; et al. Longitudinal association between selenium levels and hypertension in a rural elderly Chinese cohort. J. Nutr. Health Aging 2016, 20, 983–988. [CrossRef] [PubMed]

36. Vinceti, M.; Michalke, B.; Malagoli, C.; Eichmuller, M.; Filippini, T.; Tondelli, M.; Bargellini, A.; Vinceti, G.; Zamboni, G.; Chiari, A. Selenium and selenium species in the etiology of Alzheimer’s dementia: The potential for bias of the case-control study design. J. Trace Elem. Med. Biol. 2019, 53, 154–162. [CrossRef] [PubMed]

37. Bleys, J.; Navas-Acien, A.; Stranges, S.; Menke, A.; Miller, E.R., 3rd; Guallar, E. Serum selenium and serum lipids in US adults. Am. J. Clin. Nutr. 2008, 88, 416–423. [CrossRef] [PubMed]

38. Cold, F.; Winther, K.H.; Pastor-Barriuso, R.; Rayman, M.P.; Guallar, E.; Nybo, M.; Griffin, B.A.; Stranges, S.; Cold, S. Randomised controlled trial of the effect of long-term selenium supplementation on plasma cholesterol in an elderly Danish population. Br. J. Nutr. 2015, 114, 1807–1818. [CrossRef] [PubMed]

39. Laclaustra, M.; Stranges, S.; Navas-Acien, A.; Or dovas, J.M.; Guallar, E. Serum selenium and selenium lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003–2004. Atherosclerosis 2010, 210, 643–648. [CrossRef]

40. Rayman, M.P.; Stranges, S.; Griffin, B.A.; Pastor-Barriuso, R.; Guallar, E. Effect of supplementation with high-selenium yeast on plasma lipids: A randomized trial. Ann. Intern. Med. 2011, 154, 656–665. [CrossRef]

41. Stranges, S.; Laclaustra, M.; Ji, C.; Cappuccio, F.P.; Navas-Acien, A.; Or dovas, J.M.; Rayman, M.; Guallar, E. Higher selenium status is associated with adverse blood lipoprotein profile in British adults. J. Nutr. 2010, 140, 81–87. [CrossRef]

42. Tinkov, A.A.; Bogdanski, P.; Skrypnik, D.; Skrypnik, K.; Skalny, A.V.; Aaseth, J.; Skalnaya, M.G.; Suliburska, J. Trace element and mineral levels in serum, hair, and urine of obese women in relation to body composition, blood pressure, lipid profile, and insulin resistance. Biomolecules 2021, 11, 689. [CrossRef] [PubMed]

43. Filippini, T.; Adani, G.; Malavolti, M; Garutti, C.; Cilloni, S.; Vinceti, G.; Zamboni, G; Tondelli, M.; Galli, C.; Costa, M.; et al. Dietary habits and risk of early-onset dementia in an Italian case-control study. Nutrients 2020, 12, 3682. [CrossRef]

44. Saito, Y. Selenoprotein P as an in vivo redox regulator: Disorders related to its deficiency and excess. J. Clin. Biochem. Nutr. 2020, 66, 1–7. [CrossRef] [PubMed]

45. Tinkov, A.A.; Ajsuvakova, O.P.; Filippini, T.; Zhou, J.-C.; Lei, X.G.; Gatiatulina, E.R.; Michalke, B.; Skalnaya, M.G.; Vinceti, M.; Aschner, M.; et al. Selenium and selenoproteins in adipose tissue physiology and obesity. Biomolecules 2020, 10, 658. [CrossRef] [PubMed]

46. Vinceti, M.; Filippini, T.; Cilloni, S.; Bargellini, A.; Vergoni, A.V.; Tsatsakis, A.; Ferrante, M. Health risk assessment of environmental selenium: Emerging evidence and challenges. Mol. Med. Rep. 2017, 15, 3323–3335. [CrossRef] [PubMed]

47. Gammelgaard, B.; Sturup, S.; Christensen, M.V. Human urinary excretion and metabolism of (82)Se-enriched selenite and selenate determined by LC-ICP-MS. Metallomics 2012, 4, 149–155. [CrossRef]

48. Kokarnig, S.; Tsirigotaki, A.; Wiesenhofer, T.; Lackner, V.; Francesconi, K.A.; Pergantis, S.A.; Kuehnelt, D. Concurrent quantitative HPLC-mass spectrometry profiling of small selenium species in human serum and urine after ingestion of selenium supplements. J. Trace Elem. Med. Biol. 2015, 29, 83–90. [CrossRef] [PubMed]

49. EFSA. Scientific opinion on dietary reference values for selenium. EFSA J. 2014, 12, 3846. [CrossRef]

50. Gao, H.; Hagg, S.; Sjögren, P.; Lambert, P.C.; Ingelsson, E.; van Dam, R.M. Serum selenium in relation to measures of glucose metabolism and incidence of type 2 diabetes in an older Swedish population. Diabet. Med. 2014, 31, 787–793. [CrossRef]
51. Oo, S.M.; Misu, H.; Saito, Y.; Tanaka, M.; Kato, S.; Kita, Y.; Takayama, H.; Takeshita, Y.; Kanamori, T.; Nagano, T.; et al. Serum selenoprotein P but not selenium, predicts future hyperglycemia in a general Japanese population. Sci. Rep. 2018, 8, 16727. [CrossRef] [PubMed]

52. Bulka, C.M.; Persky, V.W.; Daviglus, M.L.; Durazo-Arvizu, R.A.; Argos, M. Multiple metal exposures and metabolic syndrome: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2011-2014. Environ. Res. 2019, 168, 397–405. [CrossRef]

53. Pounis, G.; Costanzo, S.; Persichillo, M.; de Curtis, A.; Sieri, S.; Vinceti, M.; Zito, F.; Di Castelnuovo, A.F.; Donati, M.B.; de Gaetano, G.; et al. Mushroom and dietary selenium intakes in relation to fasting glucose levels in a free-living Italian adult population: The Moli-sani Project. Diabetes Metab. 2014, 40, 34–42. [CrossRef]

54. Zhou, L.; Luo, C.; Yin, J.; Zhu, Y.; Li, P.; Chen, S.; Sun, T.; Xie, M.; Shan, Z.; Cao, B.; et al. Diverse associations of plasma selenium concentrations and SELENOP gene polymorphism with metabolic syndrome and its components. Oxid. Med. Cell Longev. 2020, 2020, 5343014. [CrossRef] [PubMed]

55. Akbaraly, T.N.; Arnaud, J.; Rayman, M.P.; Hininger-Favier, I.; Roussel, A.M.; Berr, C.; Fontbonne, A. Plasma selenium and risk of dysglycemia in an elderly French population: Results from the prospective Epidemiology of Vascular Ageing Study. Nutr. Metab. 2010, 7, 21. [CrossRef]

56. Christensen, K.; Werner, M.; Malecki, K. Serum selenium and lipid levels: Associations observed in the National Health and Nutrition Examination Survey (NHANES) 2011–2012. Environ. Res. 2015, 140, 76–84. [CrossRef]

57. Fang, H.; He, X.; Wu, Y.; Chen, S.; Zhang, M.; Pan, F.; Huang, J.; Liu, A. Association Between Selenium Level in Blood and Glycolipid Metabolism in Residents of Enshi Prefecture, China. Biol. Trace Elem. Res. 2021, 199, 2456–2466. [CrossRef]

58. Huang, Y.Q.; Shen, G.; Lo, K.; Huang, J.Y.; Liu, L.; Chen, C.L.; Yu, Y.L.; Sun, S.; Zhang, B.; Feng, Y.Q. Association of circulating selenium concentration with dyslipidemia: Results from the NHANES. J. Trace Elem. Med. Biol. 2020, 58, 126438. [CrossRef]

59. National Research Council. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; Institute of Medicine: Washington, DC, USA, 2000.

60. Winther, K.H.; Bonnema, S.J.; Cold, F.; Debrabant, B.; Nybo, M.; Cold, S.; Hegedus, L. Does selenium supplementation affect thyroid function? Results from a randomized, controlled, double-blinded trial in a Danish population. Eur. J. Endocrinol. 2015, 172, 657–667. [CrossRef] [PubMed]

61. Mao, J.; Pop, V.J.; Bath, S.C.; Vader, H.L.; Redman, C.W.; Rayman, M.P. Effect of low-dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild-to-moderate iodine deficiency. Eur. J. Nutr. 2016, 55, 55–61. [CrossRef] [PubMed]

62. Combs, G.F., Jr.; Midthune, D.N.; Patterson, K.Y.; Canfield, W.K.; Hill, A.D.; Levander, O.A.; Taylor, P.R.; Moler, J.E.; Patterson, B.H. Effects of selenomethionine supplementation on selenium status and thyroid hormone concentrations in healthy adults. Am. J. Clin. Nutr. 2009, 89, 1808–1814. [CrossRef] [PubMed]

63. Galan, P.; Viteri, F.E.; Bertrais, S.; Czernichow, S.; Faure, H.; Arnaud, J.; Ruffieux, D.; Chenal, S.; Arnauld, N.; Favier, A.; et al. Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. Eur. J. Clin. Nutr. 2005, 59, 1181–1190. [CrossRef] [PubMed]

64. Morford, J.; Mauvais-Jarvis, F. Sex differences in the effects of androgens acting in the central nervous system on metabolism. Dialogues Clin. Neurosci. 2016, 18, 415–424. [CrossRef]

65. Choe, S.Y.; Kim, S.J.; Kim, H.G.; Lee, J.H.; Choi, Y.; Lee, H.; Kim, Y. Evaluation of estrogenicity of major heavy metals. Sci. Total Environ. 2003, 312, 15–21. [CrossRef]

66. Lee, S.O.; Nadiminty, N.; Wu, X.X.; Lou, W.; Dong, Y.; Ip, C.; Onate, S.A.; Gao, A.C. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res. 2005, 65, 3487–3492. [CrossRef] [PubMed]

67. Schomburg, L.; Schweizer, U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim. Biophys. Acta 2009, 1790, 1453–1462. [CrossRef]

68. Seale, L.A.; Ogawa-Wong, A.N.; Berry, M.J. Sexual dimorphism in selenium metabolism and selenoproteins. Free Radic. Biol. Med. 2018, 127, 198–205. [CrossRef]

69. Stoca, A.; Pentecost, E.; Martin, M.B. Effects of selenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. J. Cell. Biochem. 2000, 79, 282–292. [CrossRef]

70. Stranges, S.; Marshall, J.R.; Natarajan, R.; Donahue, R.P.; Trevisan, M.; Combs, G.F.; Cappuccio, F.P.; Ceriello, A.; Reid, M.E. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann. Intern. Med. 2007, 147, 217–223. [CrossRef]

71. Vinceti, M.; Bonaccio, M.; Filippini, T.; Costanzo, S.; Wise, L.A.; Di Castelnuovo, A.; Ruggiero, E.; Persichillo, M.; Cerletti, C.; Donati, M.B.; et al. Dietary selenium intake and risk of hospitalization for type 2 diabetes in the Moli-sani study cohort. Nutr. Metab. Cardiovasc. Dis. 2021, 31, 1738–1746. [CrossRef]

72. Michalke, B.; Halbach, S.; Nischwitz, V. JEM spotlight: Metal speciation related to neurotoxicity in humans. J. Environ. Monit. 2009, 11, 939–954. [CrossRef]

73. Weekley, C.M.; Harris, H.H. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem. Soc. Rev. 2013, 42, 8870–8894. [CrossRef] [PubMed]
74. Dauplais, M.; Mahou, P.; Plateau, P.; Lazard, M. Exposure to the methylselenol precursor dimethyldiselenide induces a reductive endoplasmic reticulum stress in *Saccharomyces cerevisiae*. *Int. J. Mol. Sci.* 2021, 22, 5467. [CrossRef]

75. Rayman, M.P. Selenium intake, status, and health: A complex relationship. *Hormones* 2020, 19, 9–14. [CrossRef] [PubMed]

76. Kondaparthi, P.; Deore, M.; Naqvi, S.; Flora, S.J.S. Dose-dependent hepatic toxicity and oxidative stress on exposure to nano and bulk selenium in mice. *Environ. Sci. Pollut. Res. Int.* 2021. [CrossRef] [PubMed]

77. Lazard, M.; Dauplais, M.; Blanquet, S.; Plateau, P. Recent advances in the mechanism of selenoamino acids toxicity in eukaryotic cells. *Biomol. Concepts* 2017, 8, 93–104. [CrossRef] [PubMed]

78. Vamanu, E.; Rai, S.N. The Link between Obesity, Microbiota Dysbiosis, and Neurodegenerative Pathogenesis. *Diseases* 2021, 9, 45. [CrossRef]

79. Pereira, A.M.; Pinna, C.; Biagi, G.; Stefanelli, C.; Maia, M.R.G.; Matos, E.; Segundo, M.A.; Fonseca, A.J.M.; Cabrita, A.R.J. Supplemental selenium source on gut health: Insights on fecal microbiome and fermentation products of growing puppies. *FEMS Microbiol. Ecol.* 2020, 96, fiaa212. [CrossRef]